Technology | Proton Therapy | August 18, 2016

FDA Clears IBA’s Compact Proton Therapy System

ProteusONE is the first FDA cleared and CE marked compact solution using image guided IMPT

ProteusONE, IBA, FDA approval, FDA clearance of ProteusONE, compact proton therapy
ProteusONE, IBA, FDA approval, FDA clearance of ProteusONE, compact proton therapy

A room layout for the IBA ProteusOne compact proton therapy system.

August 18, 2016 — IBA (Ion Beam Applications SA) has received U.S. Food and Drug Administration (FDA) clearance for its new super conducting accelerator, which is the latest development, essential to the ProteusONE compact Intensity Modulated Proton Therapy (IMPT) solution, that required approval from regulatory authorities. 

The FDA clearance makes ProteusONE, the only compact proton therapy solution in the industry, that is certified to treat patients in the United States with optimized pencil beam scanning (PBS) and image guidance.
IBA has already signed 13 contracts to provide its compact proton therapy solution worldwide. The FDA clearance is an important milestone that will ensure on-time delivery of all of IBA’s current and future contracts.
“FDA clearance of our ProteusONE's new super conducting accelerator will be a significant market accelerator for proton therapy in the United States, because ProteusONE provides the most advanced treatment mode within the most compact and affordable system,” said Beth Klein, president of IBA Proton Therapy North America. “Any hospital considering proton therapy can now afford it through the ProteusONE’s lower capital and operating costs without making any clinical compromise. Ultimately, this will make proton therapy more accessible to the radiation therapy patients in the United States who can benefit from it.”
The ProteusONE is the world’s only FDA cleared and CE marked compact solution that uses image guided IMPT. With IBA’s industrialized production together with full CE approval and FDA clearance, IBA is now able to install complete proton therapy system in less than 12 months.
The ProteusONE is equipped with pencil beam scanning, a technology that offers high sub-millimeter precision treatment, which allows delivery of very high levels of conformity and dose uniformity, even in complex-shaped tumors, whilst at the same time sparing the surrounding healthy tissue.
For more information:

Related Content

he Centers for Medicare and Medicaid Services (CMS) published the “Specialty Care Models to Improve Quality of Care and Reduce Expenditures (CMS-5527)” final rule.

Getty Images

News | Radiation Oncology | September 29, 2020
September 29, 2020 — On Sept.
Important milestone demonstrates the unrivalled experience, technological innovation and global market leadership of IBA and its clinical partners
News | Proton Therapy | September 25, 2020
September 25, 2020 — IBA (Ion Beam Applications SA) announced that more than 100,000 patients have now been treated w
Philips Azurion Lung Edition supports high precision diagnosis and minimally invasive therapy in one room
News | Lung Imaging | September 21, 2020
September 21, 2020 — Philips introduced...
Final rule includes mandatory participation for nearly 1,000 practices and does not allow sufficient time for transition

Getty Images

News | Radiation Oncology | September 21, 2020
September 21, 2020 — In response to the September 18 ...
According to a new report published by P&S Intelligence, the global radiotherapy market is expected to expand from $7.2M in 2019 to $17M by 2030.

Image courtesy of Accuray

Feature | Radiation Therapy | September 21, 2020 | By Melinda Taschetta-Millane
According to a...
Breast cancer patients whose disease has spread to their brains fare better if their metastases are picked up before they begin to cause symptoms, according to a study presented at the 12th European Breast Cancer Conference.

Getty Images

News | Breast Imaging | September 21, 2020
September 21, 2020 — Breast cancer patients whose disease has spread to their brains fare better if their metastases
Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s
High-intensity focused ultrasound (HIFU), a technology used to treat localized prostate cancer, has shown adequate control of prostate cancer while avoiding major side effects of surgery or radiation therapy, according to a new study in The Journal of Urology, Official Journal of the American Urological Association

Getty Images

News | Prostate Cancer | September 08, 2020
September 8, 2020 — Approved by the US Food and Drug Administration (FDA) in 2015 for prostate tissue ablation, the h